5163 Methylation in breast cancer and correlate ER with tumor phenotypes and prognostic factors

13%), tumor size (T1 59% T2 39% T3 1.6%) and grade (G1 32% G2 39% G3 15%). Results: Median follow-up was 47 months. Actuarial (OS and DFS) at 4 years were luminal A (99.3% and 95.8%), luminal B (95.6% and 80.4%), Her2 (89.8% and 80.9%) and triple negative (74.6% and 58.7%), p = 0.0001; for N0 (98.8% and 93.9%) N1−3 (90.8% and 83.6%) and N > 4 (87.1% and 71.8%), p = 0.0001. Significant independent prognostic factor for OS were BC subtypes (with relative risk (RR) luminal B 4.7, Her2 3.6 and triple negative 12.08 referent to luminal A, p = 0.0001), and the number of positive nodes (N1−3 RR = 6.6 and N > 4 8.3 referent to N0 category, p = 0.004), respectively. Significant independent prognostic factor for DFS were BC subtypes (with relative risk (RR) luminal B 4.8, Her2 3.9 and triple negative 7.7 referent to luminal A, p = 0.0001), the number of positive nodes >4 (RR 2.01 referent to N0 category, p = 0.049) and tumor size (T2 RR 2.28 referent to T1 category, p = 0.004). Conclusions: A simple immunopanel can divide breast cancers into biologic subtypes with independent prognostic effects and provides additional information to nodal status. Triple negative status emerged as a strong adverse prognostic factor.